CN116621820A - 一种两性离子荧光化合物及其制备方法和应用 - Google Patents
一种两性离子荧光化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116621820A CN116621820A CN202310588107.1A CN202310588107A CN116621820A CN 116621820 A CN116621820 A CN 116621820A CN 202310588107 A CN202310588107 A CN 202310588107A CN 116621820 A CN116621820 A CN 116621820A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- reaction
- zwitterionic
- zwitterionic fluorescent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000000090 biomarker Substances 0.000 claims abstract description 21
- 230000004044 response Effects 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 84
- 238000006243 chemical reaction Methods 0.000 claims description 46
- 238000006482 condensation reaction Methods 0.000 claims description 36
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 230000017858 demethylation Effects 0.000 claims description 14
- 238000010520 demethylation reaction Methods 0.000 claims description 14
- 238000006722 reduction reaction Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- 229940125782 compound 2 Drugs 0.000 claims description 6
- 229940126214 compound 3 Drugs 0.000 claims description 6
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 4
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 4
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 4
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims description 4
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims description 4
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 4
- 229940126657 Compound 17 Drugs 0.000 claims description 4
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 4
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims description 4
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 4
- 229940125797 compound 12 Drugs 0.000 claims description 4
- 229940126543 compound 14 Drugs 0.000 claims description 4
- 229940125758 compound 15 Drugs 0.000 claims description 4
- 229940126142 compound 16 Drugs 0.000 claims description 4
- 229940125810 compound 20 Drugs 0.000 claims description 4
- 229940126086 compound 21 Drugs 0.000 claims description 4
- 229940126208 compound 22 Drugs 0.000 claims description 4
- 229940125833 compound 23 Drugs 0.000 claims description 4
- 229940125961 compound 24 Drugs 0.000 claims description 4
- 229940125846 compound 25 Drugs 0.000 claims description 4
- 229940125851 compound 27 Drugs 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 2
- 229940125773 compound 10 Drugs 0.000 claims description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 239000012634 fragment Substances 0.000 abstract description 6
- 230000003287 optical effect Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 abstract description 3
- 125000001424 substituent group Chemical group 0.000 abstract description 3
- 239000000975 dye Substances 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 26
- 239000000523 sample Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000001035 drying Methods 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- -1 polysaccharide compounds Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000009304 Acute Kidney Injury Diseases 0.000 description 6
- 208000033626 Renal failure acute Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 201000011040 acute kidney failure Diseases 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 102000004091 Caspase-8 Human genes 0.000 description 5
- 108090000538 Caspase-8 Proteins 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 5
- 239000012300 argon atmosphere Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 208000014001 urinary system disease Diseases 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 229940105442 cisplatin injection Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 125000000542 sulfonic acid group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- RRWOBMRVLZQKEY-UHFFFAOYSA-N [2-(benzotriazol-1-yloxy)pyrrolidin-1-yl]-dipyrrolidin-1-ylphosphane Chemical compound C1CCCN1P(N1C(CCC1)ON1C2=CC=CC=C2N=N1)N1CCCC1 RRWOBMRVLZQKEY-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940113720 aminosalicylate Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- UFCZCJYLUGMEJH-UHFFFAOYSA-N dodecanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCCCCCCCCCC(O)=O UFCZCJYLUGMEJH-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229930182851 human metabolite Natural products 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明涉及一种两性离子荧光化合物及其制备方法和应用。该两性离子荧光化合物以半花菁染料结构的衍生物作为荧光团,以及在两端分别连接R2基团(‑OH、‑NH2或含有生物标志物响应基团)和含有季铵的片段,不仅具有较高的灵敏度、较好的生物相容性和光学稳定性,而且通过和取代基团或片段的配合而具有良好的水溶性与肾清除效率,作为荧光探针,可更为精准地对疾病进行早期诊断,术中导航治疗,组织器官功能评价等。
Description
技术领域
本发明涉及生物医学技术领域,更具体地,涉及一种两性离子荧光化合物及其制备方法和应用。
背景技术
泌尿系统由肾脏、输尿管、膀胱、尿道组成,是人体代谢产物的重要排泄途径。在排泄过程中,异常的体内代谢废物、外来微生物、药物等易引起周围组织、细胞的感染和损伤,进而导致一系列疾病。当前泌尿系统疾病的临床诊断常依赖于传统影像学手段,然而这些方法存在高电离辐射、灵敏度低、有创及成本高等缺陷,难以早期诊断并实施干预。与传统影像学技术相比,光学成像/检测技术具有高灵敏度、特异性强、安全性高以及便捷易普及等优势。因此,利用非侵入性、无电离辐射、高特异性和灵敏度的荧光成像技术检测泌尿系统疾病具有极好的应用前景。
目前用于肾脏疾病检测的探针主要包括无机纳米探针与有机分子探针。无机纳米探针的代谢受肾小球基底膜孔径的限制,对纳米探针大小具有严格的选择性,仅水合直径小于6nm且具有低蛋白结合率的无机纳米颗粒才能够有效的通过肾脏排出。其次,无机纳米材料的代谢速度较慢,在体内循环时可被肝脏的内皮网状系统捕获蓄积,导致长期的、潜在的生物毒性。此外,无机纳米探针的制备规模受限、价格高昂、合成生产重现性与定量存在困难。相比之下,有机分子探针具有代谢速度快、生物相容性高、结构可修饰等优势,在生物医学领域具有广泛的应用包括细胞成像,肿瘤诊断治疗及临床术中导航等。利用有机分子构建肾清除型的荧光探针主要通过偶联亲水性大分子(如聚乙二醇、环糊精、多糖化合物等)来实现良好的水溶性和肾脏代谢效果。比如,公开号为CN115947946A的专利就提供了一种亲水性的有机大分子肾清除型的荧光探针。然而由于体内存在大量复杂的糖蛋白酶,导致此类亲水性有机大分子标记的分子探针容易在体内发生降解;此外,荧光偶联标记亲水性大分子通常属于聚合物,故常出现合成工艺不稳定,不同批次间存在较大差异等问题,影响后续生物应用。
因此,开发单分子、无标记的肾清除型的荧光探针对于泌尿系统疾病的诊疗具有重要意义。
发明内容
本发明的首要目的是克服上述现有现有的有机大分子肾清除型的荧光探针在体内易降解,且产品批次不稳定的问题,提供一种两性离子荧光化合物。
本发明的进一步目的是提供上述两性离子荧光化合物的制备方法。
本发明的进一步目的是提供上述两性离子荧光化合物或其药学上可接受的盐、溶剂化物、对映异构体、非对映异构体、互变异构体在制备荧光探针中的应用。
本发明的上述目的通过以下技术方案实现:
一种两性离子荧光化合物,具有式(Ⅰ)~式(Ⅴ)任一所示的结构:
其中,R1为-COO-、-SCN、-N3或/>R2为-OH、-NH2、A为自消除基团,B为生物标志物响应基团;n为0~50的整数,n1为0~20的整数,n2为0~20的整数。
本发明以特定的主体结构作为荧光团(发色团),在主体结构的一端的特定取代位上连接特定的R2基团(-OH、-NH2或含有生物标志物响应基团),在主体结构的另一端的特定取代位上分别连接磺酸基和含有季铵的片段,获得两性离子荧光化合物。其中,荧光团具有较好的量子产率,生物标志物响应基团可被对应的生物标志物激活,进而引起分子结构与光学性能的改变,产生更强的荧光信号,并可利用荧光成像技术实时监测;该两性离子荧光化合物不仅具有较高的灵敏度、较好的生物相容性和光学稳定性,而且通过和取代基团或片段的配合而具有良好的水溶性与肾清除效率。
需要说明的是,式(Ⅰ)~式(Ⅴ)中都属于吲哚类化合物结构,在本发明中可以等同替换;/>比式/>多一个苯环,共轭效应增强。两者都具有共轭效应,随着苯基个数增加,紫外吸收波长逐渐增长,也都可以发射出荧光,并且荧光波长也逐渐增加。
本发明提供的两性离子荧光化合物可作为荧光探针,制备成多种给药方式(静脉注射、腹腔注射或者喷洒)的制剂。以静脉注射方式为例,本发明的两性离子荧光化合物经静脉注射后,由于健康组织生物标志物表达含量非常低,荧光探针的生物标志物响应基团未被激活,不发生探针电子云密度的改变,因此在健康组织中不会检测到明显的荧光光学信号。当泌尿系统发生病变,生物标志物大量表达,经肾脏代谢的两性离子荧光化合物被激活,释放较强的荧光信号,可通过荧光成像实时监测,实现泌尿系统病变部位的动态监测以及病变区域的可视化识别,为手术的精准化治疗提供更精确的指导,以提高手术疗效与患者预后,有望为人类的疾病诊断和治疗提供一种新的辅助方法。
优选地,所述自消除基团A为
应当理解的是,自消除基团A为时,左侧连接位点与生物标志物响应基团B连接;自消除基团A为/>时,左侧连接位点与B连接;自消除基团A为/>时,右侧连接位点与B连接。
生物标志物响应基团B可根据目标生物标志物的不同进行选择,本发明在此提供一系列不同的生物标志物响应基团。
优选地,所述生物标志物响应基团B为
经研究,上述生物标志物响应基团与生物标志物之间特异性激发的关系如下:
优选地,所述n为1~20的整数。
优选地,n1为1~10的整数。
优选地,n2为1~10的整数。
优选地,具有如下所示结构:
上述两性离子荧光化合物的制备方法,包括如下步骤:
S1.式(1)所示的化合物1和式(6)所示的化合物6发生缩合反应,得到式(8)所示的化合物8;
或式(1)所示的化合物1和式(7)所示的化合物7发生缩合反应,得到式(9)所示的化合物9;
或式(2)所示的化合物2和式(6)所示的化合物6发生缩合反应,得到式(12)所示的化合物12;
或式(2)所示的化合物2和式(7)所示的化合物7发生缩合反应,得到式(13)所示的化合物13;
或式(3)所示的化合物3和式(6)所示的化合物6发生缩合反应,得到式(16)所示的化合物16;
或式(3)所示的化合物3和式(7)所示的化合物7发生缩合反应,得到式(17)所示的化合物17;
或式(4)所示的化合物4和式(6)所示的化合物6发生缩合反应,得到式(20)所示的化合物20;
或式(4)所示的化合物4和式(7)所示的化合物7发生缩合反应,得到式(21)所示的化合物21;
或式(5)所示的化合物5和式(6)所示的化合物6发生缩合反应,得到式(24)所示的化合物24;
或式(5)所示的化合物5和式(7)所示的化合物7发生缩合反应,得到式(25)所示的化合物25;
S2.化合物8发生脱甲基保护反应,得式(10)所示的化合物10;
或化合物12发生脱甲基保护反应,得式(14)所示的化合物14;
或化合物16发生脱甲基保护反应,得式(18)所示的化合物18;
或化合物20发生脱甲基保护反应,得式(22)所示的化合物22;
或化合物24发生脱甲基保护反应,得式(26)所示的化合物26;
或化合物9经还原反应,得式(11)所示的化合物11;
或化合物13经还原反应,得式(15)所示的化合物15;
或化合物17经还原反应,得式(19)所示的化合物19;
或化合物21经还原反应,得式(23)所示的化合物23;
或化合物25经还原反应,得式(27)所示的化合物27;
S3.化合物10与R2-H发生取代反应,即得如式(Ⅰ)所示两性离子荧光化合物;
或化合物14与R2-H发生取代反应,即得如式(Ⅱ)所示两性离子荧光化合物;
或化合物18与R2-H发生取代反应,即得如式(Ⅲ)所示两性离子荧光化合物;
或化合物22与R2-H发生取代反应,即得如式(Ⅳ)所示两性离子荧光化合物;
或化合物26与R2-H发生取代反应,即得如式(Ⅴ)所示两性离子荧光化合物;
或化合物11与R2-H发生缩合反应,即得如式(Ⅰ)所示两性离子荧光化合物;
或化合物15与R2-H发生缩合反应,即得如式(Ⅱ)所示两性离子荧光化合物;
或化合物19与R2-H发生缩合反应,即得如式(Ⅲ)所示两性离子荧光化合物
或化合物23与R2-H发生缩合反应,即得如式(Ⅳ)所示两性离子荧光化合物;
或化合物27与R2-H发生缩合反应,即得如式(Ⅴ)所示两性离子荧光化合物;
优选地,步骤S1中所述缩合反应的温度为45~100℃,时间为5~12h。
优选地,步骤S1中所述缩合反应选用的溶剂为无水乙醇、无水甲醇、N,N-二甲基甲酰胺或乙酸酐中的一种或几种,选用的活化剂为碳酸钾、碳酸铯、醋酸钠或醋酸钾中的一种或几种。
优选地,步骤S2中所述脱甲基保护反应的温度为0~30℃,时间为5~12h;步骤S2中所述还原反应的温度为45~100℃,时间为5~12h。
优选地,步骤S2中所述脱甲基保护反应选用的溶剂为乙醇、二氯甲烷、甲醇或N,N-二甲基甲酰胺中的一种或几种,选用的活化剂为三溴化硼、氯化铝、乙硫醇钠或三甲基碘硅烷中的一种或几种;步骤S2中所述还原反应选用的溶剂为乙醇、甲醇、N,N-二甲基甲酰胺或水中的一种或几种,选用的还原剂为钯碳、氢气、氯化亚锡或铁粉中的一种或几种。
优选地,步骤S3中所述取代反应的温度为45~100℃,时间为5~12h;步骤S3中所述缩合反应的温度为0~45℃,时间为8~24h。
优选地,步骤S3中所述取代反应选用的溶剂为无水甲醇、无水N,N-二甲基甲酰胺、无水乙腈或无水四氢呋喃中的一种或几种;步骤S3中所述缩合反应选用的溶剂为无水甲醇、无水N,N-二甲基甲酰胺、无水二氯甲烷或无水乙腈中的一种或几种,选用的缩合试剂为2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸盐(HATU)、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDCI)、二环己基碳二亚胺(DCC)或六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷(PyBop)中的一种或几种,选用的活化剂为碳酸钾、N,N-二异丙基乙胺、三乙胺、吡啶或甲氧苄啶中的一种或几种。
优选地,步骤S1中所述化合物2通过如下步骤制备得到:
S11.式(28)所示的化合物28与式(29)所示的化合物29发生取代反应得到化合物2;
更为优选地,步骤S11所述的取代反应为80~150℃,时间为24~72h,溶剂为N,N-二甲基甲酰胺、甲苯或邻二氯苯中的一种或几种。
优选地,步骤S1中所述化合物3通过如下步骤制备得到:
S12.式(30)所示的化合物30与式(31)所示的化合物31发生取代反应得到化合物3;
更为优选地,步骤S12所述的取代反应温度为80~150℃,时间为24~72h,溶剂为N,N-二甲基甲酰胺、甲苯或邻二氯苯中的一种或几种;
优选地,步骤S1中所述化合物7通过如下步骤制备得到:
S13.式(32)所示的化合物32发生溴代反应得式(33)所示的化合物33;
S14.化合物33与式(34)所示的化合物34发生成环反应得到化合物7;
更为优选地,步骤S13所述的溴代反应温度为0~30℃,时间为4~12h,溶剂为N,N-二甲基甲酰胺、二氯甲烷、四氢呋喃或乙腈中的一种或几种;
更为优选地,步骤S14所述的成环反应温度0~30℃,时间为4~12h,溶剂为N,N-二甲基甲酰胺、二氯甲烷、四氢呋喃或乙腈中的一种或几种,活化剂为碳酸钾、碳酸铯、醋酸钠或醋酸钾中的一种或几种。
上述两性离子荧光化合物或其药学上可接受的盐、溶剂化物、对映异构体、非对映异构体、互变异构体在制备荧光探针中的应用也在本发明的保护范围内。
优选地,所述荧光探针为肾清除型的荧光探针。
优选地,所述荧光探针为常亮型荧光探针或激发型荧光探针。
优选地,所述药学上可接受的盐为盐酸盐、氢溴酸盐、硝酸盐、甲基硝酸盐、硫酸盐、硫酸氢盐、氨基硫酸盐、磷酸盐、乙酸盐、羟基乙酸盐、苯基乙酸盐、丙酸盐、丁酸盐、异丁酸盐、戊酸盐、马来酸盐、羟基马来酸盐、丙烯酸盐、延胡索酸盐、苹果酸盐、酒石酸盐、柠檬酸盐、水杨酸盐、对氨基水杨酸盐、乙醇酸盐、乳酸盐、庚酸盐、邻苯二甲酸盐、草酸盐、琥珀酸盐、苯甲酸盐、邻乙酰氧基苯甲酸盐、氯苯甲酸盐、甲基苯甲酸盐、二硝基苯甲酸盐、羟苯酸盐、甲氧基苯甲酸盐、扁桃酸盐、丹宁酸盐、甲酸盐、硬脂酸盐、抗坏血酸盐、棕榈酸盐、油酸盐、丙酮酸盐、双羟奈酸盐、丙二酸盐、月桂酸盐、戊二酸盐、谷氨酸盐、丙酸酯月桂硫酸盐、甲磺酸盐、乙磺酸盐、2-羟基乙磺酸盐、苯磺酸盐、对氨基苯磺酸盐、对甲苯磺酸盐(甲苯磺酸盐)或萘-2-磺酸盐中的至少一种。
与现有技术相比,本发明的有益效果是:
本发明提供的两性离子荧光化合物以半花菁染料结构的衍生物作为荧光团,在吲哚环上修饰磺酸基,以及在两端分别连接R2基团(-OH、-NH2或含有生物标志物响应基团)和含有季铵的片段,不仅具有较高的灵敏度、较好的生物相容性和光学稳定性,而且通过和取代基团或片段的配合而具有良好的水溶性与肾清除效率,作为荧光探针,可更为精准地对疾病进行早期诊断,术中导航治疗,组织器官功能评价等,可在未来的医学光学检查中发挥重要的作用,具有极好的应用前景。
附图说明
图1为实施例1的两性离子荧光化合物ZWCYOH1的制备方法的示意图;
图2为实施例2的两性离子荧光化合物ZWCYOH2的制备方法的示意图;
图3为实施例3的两性离子荧光化合物ZWCYOH3的制备方法的示意图;
图4为实施例4的两性离子荧光化合物ZWCYNH2的制备方法的示意图;
图5为实施例5的两性离子荧光化合物ZWCYNH2P的制备方法的示意图;
图6为实施例1~4的两性离子荧光化合物ZWCYOH1、ZWCYOH2、ZWCYOH3、ZWCYNH2的紫外吸收光谱图;
图7为实施例1~4的两性离子荧光化合物ZWCYOH1、ZWCYOH2、ZWCYOH3、ZWCYNH2的荧光光谱图;
图8为实施例1~4的两性离子荧光化合物ZWCYOH1、ZWCYOH2、ZWCYOH3、ZWCYNH2注射后24h内的尿液回收率;
图9为实施例5的两性离子荧光化合物ZWCYNH2P体外蛋白酶响应的荧光光谱变化;
图10为实施例5的两性离子荧光化合物ZWCYNH2P在急性肾损伤小鼠模型中的活体成像图;
图11为实施例5的两性离子荧光化合物ZWCYNH2P在急性肾损伤小鼠模型中的离体器官成像图。
具体实施方式
为了更清楚、完整的描述本发明的技术方案,以下通过具体实施例进一步详细说明本发明,应当理解,此处所描述的具体实施例仅用于解释本发明,并不用于限定本发明,可以在本发明权利限定的范围内进行各种改变。
实施例1
本实施例提供一种两性离子荧光化合物,其制备方法的示意图见图1,具体包括如下步骤:
1.取100mL的双口圆底烧瓶,氩气氛围下,依次加入无水二氯甲烷(30mL)、N,N-二甲基甲酰胺(6mL,77.5mmol)、三溴化磷(2mL,21.4mmol),常温搅拌30min后,加入化合物A1(2mL,19.3mmol),常温搅拌过夜。反应结束,将反应液缓慢滴加到冰冷的饱和碳酸氢钠溶液中,旋干。乙酸乙酯萃取三次,无水硫酸钠干燥,旋干,即得淡黄色至棕黄色油状液体化合物B1。无需进一步纯化处理,直接投入下一步反应。
2.取100mL的双口圆底烧瓶,氩气氛围下,依次加入化合物C1(741mg,4.9mmol)、碳酸铯(3.9g,12.1mmol)、化合物B1(764mg,4.1mmol)、N,N-二甲基甲酰胺(20mL),常温搅拌过夜。反应结束后,旋干,乙酸乙酯萃取三次,无水硫酸钠干燥后,旋干。粗产物通过柱层析分离纯化,洗脱体系为石油醚:乙酸乙酯=15:1。收集洗脱纯化后的产物,旋干即得淡黄色至棕黄色固体化合物D1(560mg,产率58%)。1H NMR(400MHz,CDCl3):δ10.32(s,1H),7.08(d,J=9.1Hz,1H),6.69–6.63(m,3H),3.84(s,2H),2.60–2.54(m,1H),2.47–2.41(m,1H),1.74–1.68(m,1H).LRMS(ESI)m/z:[M+H]+Calcd for C15H15O3243.10;Found243.10.。
3.取100mL圆底烧瓶,依次加入化合物E1(3.76g,20mmol)、醋酸(30mL)、化合物F1(3.2mL,30mmol)、无水醋酸钠(3.2g,38mmol),油浴加热至80℃,反应过夜。反应结束后无需处理,直接上样柱层析,用二氯甲烷:甲醇=15:1洗脱目标产物。旋干,即得粉色粉末状化合物G1(4.0g,产率84%)。1HNMR(400MHz,DMSO-d6):δ7.63(s,1H),7.55(d,J=7.9Hz,1H),7.34(d,J=7.9Hz,1H),2.21(s,3H),1.25(s,6H).LRMS(ESI)m/z:[M+H]+Calcd for C11H14NO3S240.07;Found 240.19.。
4.取100mL圆底烧瓶,依次加入化合物G1(1.5g,6.0mmol)、化合物H1(3.1g,12.0mmol)、甲苯(35mL)后,油浴加热至100℃,反应24h。反应结束后,旋干,用二氯甲烷洗涤,即得粉色粉末状化合物I1。无需进一步纯化处理,直接投入下一步反应。
5.取50mL圆底烧瓶,氩气氛围下,依次加入化合物I1(170mg,0.5mmol)、化合物D1(137mg,0.6mmol)、无水醋酸钠(246mg,3.0mmol)、无水乙醇(15mL)后,油浴加热至55℃,反应过夜。反应完成后,旋干,冰浴下加入三溴化硼(1.5mL,15.6mmol),继续搅拌过夜。反应结束后将反应液缓慢滴加到冰冷的饱和碳酸氢钠溶液中,旋干,高效液相色谱法分离,即得绿色粉末化合物J1(90mg,产率33%),即为两性离子荧光化合物,记为ZWCYOH1。1H NMR(400MHz,DMSO-d6):δ11.02(s,1H),8.62(d,J=14.6Hz,1H),7.91(s,1H),7.73(d,J=8.2Hz,1H),7.68(s,1H),7.56(dd,J=16.6,8.5Hz,2H),7.02(s,1H),6.90(dd,J=8.5,2.2Hz,1H),6.45(d,J=14.6Hz,1H),4.37(t,J=7.3Hz,2H),3.08(s,9H),2.80–2.67(m,4H),2.21(s,2H),1.78(s,6H),1.23(s,4H).LRMS(ESI)m/z:[M+H]+Calcd for C31H38N2O5S550.25;Found 549.92.。
本实施例提供两性离子荧光化合物的结构式如下:
其可以作为常亮型荧光探针。
实施例2
本实施例提供一种两性离子荧光化合物,其制备方法的示意图见图2,具体包括如下步骤:
1、取50mL圆底烧瓶,依次加入化合物A2(576mg,4.0mmol)、叔丁醇(15mL)、叔丁醇钾(538mg,4.8mmol)、化合物B2(0.4mL,4.0mmol)。70℃搅拌过夜。反应结束后,旋干,正己烷萃取三次,取水相,调节溶液pH至1,旋干,干燥。加入甲醇(5mL)复溶,过滤,取滤液,直接投入下一步。
2、取50mL圆底烧瓶,加入化合物C2的甲醇溶液(即第1步得到的滤液)后,加入1mol/L氢氧化钠溶液(14mL,14.0mmol)。油浴升温至70℃,反应过夜。反应结束,旋干调节溶液pH至1后,旋干,干燥。加入20mL丙酮复溶,过滤,取滤液旋干,即得化合物D2(300mg,产率36%)。LRMS(ESI)m/z:[M+H]+Calcd for C8H17O4S209.08;Found 209.12.。
3、取50mL的圆底烧瓶,依次加入化合物D2(300mg,1.4mmol)、化合物E2(188mg,1.0mol)、醋酸(10mL)。油浴升温至95℃回流过夜。反应结束后,用异丙醇溶液洗涤,过滤,取滤渣即为化合物F2(176mg,产率48%)。LRMS(ESI)m/z:[M+H]+Calcd forC14H19NO6S2362.07;Found 362.23.。
4、取100mL圆底烧瓶,依次加入化合物F2(1.3g,3.0mmol)、邻二氯苯(30mL)、化合物H1(3.2g,12.0mmol)、碘化钠(900mg,6mmol)后,油浴加热至100℃,反应24h。反应结束后,旋干,加入乙酸乙酯洗涤,即得化合物H2。无需进一步纯化处理,直接投入下一步反应。
5、取100mL双口圆底烧瓶,依次加入化合物H2(567mg,1.2mmol)、化合物D1(410mg,1.8mmol,实施例1已制得)、无水醋酸钠(590mg,2.4mmol)、无水乙醇(30mL)后,油浴加热至55℃,反应过夜。反应完成后,旋干,冰浴下加入三溴化硼(1.5mL,15.6mmol),继续搅拌过夜。反应结束后将反应液缓慢滴加到冰冷的饱和碳酸氢钠溶液中,旋干,高效液相色谱法分离,即得绿色粉末化合物I2(249mg,产率31%),即为两性离子荧光化合物,记为ZWCYOH2。1HNMR(500MHz,Methanol-d4):δ8.55(s,1H),7.91(d,J=10.4Hz,1H),7.80(s,2H),7.53(d,J=9.0Hz,1H),7.41(d,J=8.6Hz,1H),6.86(d,J=9.0Hz,2H),6.77(s,2H),6.61(d,J=8.1Hz,2H),6.29(d,J=13.5Hz,3H),4.57(s,1H),4.27–4.20(m,1H),3.85(s,1H),3.67(s,1H),3.19(dd,J=26.2,16.2Hz,1H),2.82(s,1H),2.66(d,J=23.7Hz,1H),2.33(s,1H),1.95(s,1H),1.81(s,1H),1.60(s,1H),1.31(d,J=14.9Hz,1H),1.14(s,1H).LRMS(ESI)m/z:[M+H]+Calcd for C34H43N2O8S2671.25;Found 671.77.。
本实施例提供两性离子荧光化合物的结构式如下:
其可以作为常亮型荧光探针。
实施例3
本实施例提供一种两性离子荧光化合物,其制备方法的示意图见图3,具体包括如下步骤:
1、取100mL圆底烧瓶,依次加入化合物A3(10.3g,65.0mmol)、水(16mL)、氢氧化钠(2.6g,65.0mmol)后,常温搅拌5h。反应结束,静置分层。收集有机相于一新的100mL圆底烧瓶,加入1,2-二氯乙烷(20mL)和化合物B3(8.5mL,97.5mmol),油浴升温至50℃,反应过夜。反应完成,加入乙酸乙酯洗涤,即得化合物C3(13.7g,产率87%)。1HNMR(400MHz,D2O):δ3.64(s,2H),3.44(dd,J=8.4,5.6Hz,4H),3.07(s,6H),2.91(s,2H),2.19(dd,J=11.9,7.1Hz,4H).
2、取100mL的圆底烧瓶,依次加入化合物G1(4.0g,16.0mmol,实施例1已制得)、邻二氯苯(30mL)、化合物C3(4.0g,12.0mmol)、碘化钠(1.8g,12mmol),油浴升温至100℃,反应24h。反应结束后,旋干,高效液相色谱法分离,即得粉色固体化合物D3(3.0g,产率42%)。1HNMR(500MHz,Methanol-d4):δ8.23–8.09(m,2H),8.06(s,1H),4.84–4.61(m,1H),3.88–3.76(m,2H),3.72–3.55(m,1H),3.46–3.37(m,1H),3.27–3.21(m,1H),2.92(s,1H),2.60(d,J=47.6Hz,1H),2.32(d,J=6.4Hz,1H),1.74(s,4H).LRMS(ESI)m/z:[M-H]-Calcd forC19H29N2O6S2445.15;Found 445.22.
3、取100mL双口圆底烧瓶,依次加入化合物D3(760mg,1.7mmol)、化合物D1(470mg,2.1mmol,实施例1已制得)、无水醋酸钠(845mg,10mmol)、N,N-二甲基甲酰胺(5mL)后,油浴加热至55℃反应过夜。反应完成后,旋干,冰浴下加入三溴化硼(1.5mL,15.6mmol),继续搅拌过夜。反应结束后将反应液缓慢滴加到冰冷的饱和碳酸氢钠溶液中,旋干,高效液相色谱法分离,即得绿色粉末化合物E3(379mg,产率34%),即为两性离子荧光化合物,记为ZWCYOH3。1H NMR(500MHz,Methanol-d4):δ8.29(d,J=13.7Hz,1H),7.86(s,1H),7.82(d,J=7.8Hz,1H),7.78(d,J=6.7Hz,1H),7.45(d,J=9.0Hz,1H),7.22(d,J=8.3Hz,1H),6.76(dd,J=9.1,1.6Hz,1H),6.56(s,1H),6.04(d,J=13.5Hz,1H),3.63–3.54(m,6H),3.16(s,6H),2.83(dd,J=23.2,16.7Hz,12H),2.26(dd,J=20.9,7.4Hz,6H).LRMS(ESI)m/z:[M+H]+Calcd for C33H41N2O8S2657.23;Found657.68.
本实施例提供的两性离子荧光化合物的结构式如下:
其可以作为常亮型荧光探针。
实施例4
本实施例提供一种两性离子荧光化合物,其制备方法的示意图见图4,具体包括如下步骤:
1、取100mL双口圆底烧瓶,氩气氛围下,依次加入化合物A4(500mg,3.0mmol)、碳酸铯(3.6g,10.8mmol)、N,N-二甲基甲酰胺(20mL)、化合物B1(1.4g,5.0mmol,实施例1已制得)。反应置于常温搅拌过夜。乙酸乙酯萃取三次,无水硫酸钠干燥后,旋干。粗产物通过柱层析分离纯化,洗脱体系为石油醚:乙酸乙酯=10:1。收集洗脱纯化后的产物,旋干即得淡黄色至棕黄色固体化合物B4(629mg,产率82%)。1H NMR(400MHz,CDCl3):δ10.38(s,1H),7.93(d,J=10.2Hz,2H),7.28(d,J=8.2Hz,1H),6.70(s,1H),2.68–2.62(m,2H),2.47(t,J=5.7Hz,2H),1.80–1.73(m,2H).LRMS(ESI)m/z:[M+H]+Calcd for C14H11NO4258.08;Found258.26.。
2、取100mL双口圆底烧瓶,氩气氛围下,依次加入化合物D3(1.0g,2.2mmol,实施例3已制得)、化合物B4(310mg,1.2mmol)、无水醋酸钠(590mg,7.2mmol)、N,N-二甲基甲酰胺(15mL)、酸酐(15mL)后,油浴加热至55℃反应过夜。反应完成后,旋干。加入甲醇(30mL)、氯化亚锡(4.7g,25.0mmol)的浓盐酸溶液,油浴加热至55℃反应过夜。反应完成后,滴加饱和碳酸氢钠溶液,直至pH至8。旋干,高效液相色谱法分离,即得绿色粉末化合物C4(366mg,产率56%),即为两性离子荧光化合物,记为ZWCYNH2。1H NMR(500MHz,Methanol-d4):δ8.50(d,J=13.5Hz,1H),7.78(dd,J=30.2,13.5Hz,2H),7.43(d,J=8.7Hz,1H),7.28(d,J=8.1Hz,1H),7.16(s,1H),7.01(s,1H),6.83(d,J=8.5Hz,1H),6.14(d,J=13.7Hz,1H),3.60–3.46(m,4H),3.07(s,3H),2.79(d,J=12.3Hz,2H),2.72(d,J=22.0Hz,2H),2.11(t,J=7.2Hz,3H),1.86(s,2H),1.74(d,J=8.9Hz,2H),1.51(dd,J=14.1,7.1Hz,3H),1.47–1.37(m,3H),1.21(d,J=34.8Hz,6H).LRMS(ESI)m/z:[M-H]-Calcd for C33H40N3O7S2654.24;Found654.20.。
本实施例提供的两性离子荧光化合物的结构式如下:
其可以作为常亮型荧光探针。
实施例5
本实施例提供一种两性离子荧光化合物,其在实施例4的ZWCYNH2上接上生物标志物响应基团后得到,其制备方法的示意图见图5,具体包括如下步骤:
1、取50mL圆底烧瓶,依次加入化合物A5(130mg,0.2mmol)、O-(7-氮杂苯并三唑-1-基)-N,N,N’,N’-四甲基脲六氟磷酸盐(140mg,0.4mmol)、无水N,N-二甲基甲酰胺(15mL)和N,N-二异丙基乙胺(30μL,0.2mmol)。常温搅拌20分钟后,加入实施例4得到的化合物C4(50mg,0.08mmol),继续常温搅拌,反应过夜。反应结束,旋干后,无需其它处理,即投入下一步。
5.取25mL圆底烧瓶,加入化合物B5、三氟乙酸(1mL,13mmol)。搅拌8h。反应结束,旋干,用高效液相色谱分离,即得蓝色粉末化合物C5(26mg,产率29%),即为两性离子荧光化合物,记为ZWCYNH2P。1H NMR(500MHz,D2O):δ8.58(d,J=14.3Hz,1H),8.44(s,1H),7.95(s,1H),7.89(d,J=8.3Hz,1H),7.81(s,1H),7.38(d,J=8.3Hz,1H),7.33–7.25(m,2H),6.32(d,J=14.5Hz,1H),4.71(dd,J=9.7,6.1Hz,363H),4.64–4.56(m,5H),4.42–4.32(m,3H),4.22(dd,J=13.7,7.5Hz,4H),4.02(d,J=7.5Hz,1H),3.69(d,J=7.2Hz,2H),3.66–3.59(m,2H),3.56–3.43(m,4H),3.10(s,2H),2.92(dd,J=18.2,11.0Hz,2H),2.71–2.58(m,4H),2.36–2.13(m,6H),1.99(s,1H),1.72(s,2H),1.57(d,J=4.4Hz,2H),1.40–1.20(m,6H),0.85–0.71(m,4H).LRMS(ESI)m/z:[M-H]-Calcd for C54H72N7O17S21154.45;Found1154.45.。
本实施例提供的两性离子荧光化合物结构式如下:
其可以作为激活型荧光探针。
性能测试
1.光谱测试:配制0.05mg/mL常亮型荧光探针ZWCYOH1、ZWCYOH2、ZWCYOH3、ZWCYNH2的PBS溶液和甲醇溶液。用紫外光谱仪测定各样品400~900nm的吸收光谱图,用荧光光谱仪测定各样品的荧光光谱图(激发波长:660nm)。测试结果如图6与图7所示,由于各探针的荧光团均为半花菁结构,故光谱的最大吸收与最大发射波长无明显差异。
2.肾清除效率测试:配制0.05mg/mL常亮型荧光探针ZWCYOH1、ZWCYOH2、ZWCYOH3、ZWCYNH2的PBS溶液。取12只Balb/c小鼠,随机分成3组,每组3只,小鼠尾静脉注射探针溶液75μL。注射后将小鼠单独放置在干净的代谢笼中,收集24h内的尿液并记录体积。用高效液相色谱制备探针浓度-色谱峰面积的标准曲线,计算小鼠尿液中探针的回收率。
测试结果如图8所示。ZWCYOH1、ZWCYOH2、ZWCYOH3、ZWCYNH2都可通过泌尿系统进行代谢而存在于排出的尿液中,其中,常亮型探针ZWCYOH2、ZWCYOH3、ZWCYNH2的电荷分布更加平衡,三者的尿液回收率更高,分别为88%、91%、93%,证明本发明提供的两性离子型荧光探针具有良好的肾清除效率,可实现泌尿系统疾病的检测。
ZWCYNH2P的肾清除效率测试结果相似,回收率达91%。
3.激活型探针的响应能力测试:将10μM的激活型探针ZWCYNH2P溶液与细胞凋亡蛋白酶caspase-8在37℃的缓冲溶液中孵育。测定溶液的荧光光谱变化。测试结果如图9所示,该探针的多肽序列被caspase-8蛋白酶识别并切割,溶液的荧光发射波长发生红移,荧光强度增加。
4.急性肾损伤小鼠模型的建立:取18只Balb/c小鼠,随机分成6组,分别为空白对照组(control组)、NAC对照组、模型组(12h组、24h组、48h组、72h组),每组三只。(1)control组:腹腔注射0.4mL的生理盐水;(2)AKI(急性肾损伤)模型组:腹腔注射20mg/kg的顺铂溶液,并于注射后12h、24h、48h、72h进行影像学检查;(3)NAC组:尾静脉注射400mg/kg剂量的NAC溶液,30min后腹腔注射20mg/kg的顺铂溶液,于注射顺铂后的第48h进行影像学检查。最后,小鼠被安乐死,并对各器官进行成像。
测试结果如图10所示,探针ZWCYNH2P注射进入体内后,因control组和12h组中肾脏正常无病变,caspase-8表达量相对较低,探针荧光强度亦较低。而随着注射顺铂后时间的延长,顺铂逐步损伤肾脏组织,诱发急性肾损伤,导致肾脏中caspase-8蛋白的表达逐渐上升。探针注射进入体内,其多肽序列即被caspase-8蛋白酶识别并切割,暴露游离的氨基,恢复探针的“D-π-A”结构,表现出极强的荧光。
测试结果如图11所示,肝脏的信号比肾脏信号弱,证明探针主要经肾脏代谢,而不是肝脏代谢。同时,各组的肾脏信号随顺铂注射时间的延长而增强,即capase-8蛋白的表达逐渐增多,可实现疾病的早期诊断。
显然,本发明的上述实施例仅仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明权利要求的保护范围之内。
Claims (10)
1.一种两性离子荧光化合物,其特征在于,具有式(Ⅰ)~式(Ⅴ)任一所示的结构:
其中,R1为-COO-、-SCN、-N3或/>R2为-OH、-NH2、A为自消除基团,B为生物标志物响应基团;n为0~50的整数,n1为0~20的整数,n2为0~20的整数。
2.根据权利要求1所述两性离子荧光化合物,其特征在于,所述自消除基团A为
3.根据权利要求1所述两性离子荧光化合物,其特征在于,所述生物标志物响应基团B为
4.根据权利要求1所述两性离子荧光化合物,其特征在于,所述n为1~20的整数。
5.根据权利要求1所述两性离子荧光化合物,其特征在于,具有如下所示结构:
6.权利要求1~5任一所述两性离子荧光化合物的制备方法,其特征在于,包括如下步骤:
S1.式(1)所示的化合物1和式(6)所示的化合物6发生缩合反应,得到式(8)所示的化合物8;
或式(1)所示的化合物1和式(7)所示的化合物7发生缩合反应,得到式(9)所示的化合物9;
或式(2)所示的化合物2和式(6)所示的化合物6发生缩合反应,得到式(12)所示的化合物12;
或式(2)所示的化合物2和式(7)所示的化合物7发生缩合反应,得到式(13)所示的化合物13;
或式(3)所示的化合物3和式(6)所示的化合物6发生缩合反应,得到式(16)所示的化合物16;
或式(3)所示的化合物3和式(7)所示的化合物7发生缩合反应,得到式(17)所示的化合物17;
或式(4)所示的化合物4和式(6)所示的化合物6发生缩合反应,得到式(20)所示的化合物20;
或式(4)所示的化合物4和式(7)所示的化合物7发生缩合反应,得到式(21)所示的化合物21;
或式(5)所示的化合物5和式(6)所示的化合物6发生缩合反应,得到式(24)所示的化合物24;
或式(5)所示的化合物5和式(7)所示的化合物7发生缩合反应,得到式(25)所示的化合物25;
S2.化合物8发生脱甲基保护反应,得式(10)所示的化合物10;
或化合物12发生脱甲基保护反应,得式(14)所示的化合物14;
或化合物16发生脱甲基保护反应,得式(18)所示的化合物18;
或化合物20发生脱甲基保护反应,得式(22)所示的化合物22;
或化合物24发生脱甲基保护反应,得式(26)所示的化合物26;
或化合物9经还原反应,得式(11)所示的化合物11;
或化合物13经还原反应,得式(15)所示的化合物15;
或化合物17经还原反应,得式(19)所示的化合物19;
或化合物21经还原反应,得式(23)所示的化合物23;
或化合物25经还原反应,得式(27)所示的化合物27;
S3.化合物10与R2-H发生取代反应,即得如式(Ⅰ)所示两性离子荧光化合物;
或化合物14与R2-H发生取代反应,即得如式(Ⅱ)所示两性离子荧光化合物;
或化合物18与R2-H发生取代反应,即得如式(Ⅲ)所示两性离子荧光化合物;
或化合物22与R2-H发生取代反应,即得如式(Ⅳ)所示两性离子荧光化合物;
或化合物26与R2-H发生取代反应,即得如式(Ⅴ)所示两性离子荧光化合物;
或化合物11与R2-H发生缩合反应,即得如式(Ⅰ)所示两性离子荧光化合物;
或化合物15与R2-H发生缩合反应,即得如式(Ⅱ)所示两性离子荧光化合物;
或化合物19与R2-H发生缩合反应,即得如式(Ⅲ)所示两性离子荧光化合物
或化合物23与R2-H发生缩合反应,即得如式(Ⅳ)所示两性离子荧光化合物;
或化合物27与R2-H发生缩合反应,即得如式(Ⅴ)所示两性离子荧光化合物;
7.根据权利要求6所述两性离子荧光化合物的制备方法,其特征在于,步骤S1中所述缩合反应的温度为45~100℃,时间为5~12h。
8.根据权利要求6所述两性离子荧光化合物的制备方法,其特征在于,步骤S2中所述脱甲基保护反应的温度为0~30℃,时间为5~12h;步骤S2中所述还原反应的温度为45~100℃,时间为5~12h。
9.根据权利要求6所述两性离子荧光化合物的制备方法,其特征在于,步骤S3中所述取代反应的温度为45~100℃,时间为5~12h;步骤S3中所述缩合反应的温度为0~45℃,时间为8~24h。
10.权利要求1~5任一所述两性离子荧光化合物或其药学上可接受的盐、溶剂化物、对映异构体、非对映异构体、互变异构体在制备荧光探针中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310588107.1A CN116621820A (zh) | 2023-05-23 | 2023-05-23 | 一种两性离子荧光化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310588107.1A CN116621820A (zh) | 2023-05-23 | 2023-05-23 | 一种两性离子荧光化合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116621820A true CN116621820A (zh) | 2023-08-22 |
Family
ID=87591464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310588107.1A Pending CN116621820A (zh) | 2023-05-23 | 2023-05-23 | 一种两性离子荧光化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116621820A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108135903A (zh) * | 2015-09-09 | 2018-06-08 | 目标实验室有限责任公司 | 靶向psma的nir染料及其应用 |
CN113801145A (zh) * | 2021-10-12 | 2021-12-17 | 南京大学 | 一种激活型近红外小分子荧光探针及其制备方法与应用 |
CN114377152A (zh) * | 2021-12-06 | 2022-04-22 | 中山大学 | 一种生物标志物响应型荧光示踪剂及其制备方法和应用 |
CN115947946A (zh) * | 2022-12-13 | 2023-04-11 | 中山大学 | 一种肾清除型双通道光学纳米探针及其制备方法和应用 |
CN115947777A (zh) * | 2022-12-30 | 2023-04-11 | 中山大学 | 一种近红外二区荧光化合物及其制备方法与应用 |
-
2023
- 2023-05-23 CN CN202310588107.1A patent/CN116621820A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108135903A (zh) * | 2015-09-09 | 2018-06-08 | 目标实验室有限责任公司 | 靶向psma的nir染料及其应用 |
CN113801145A (zh) * | 2021-10-12 | 2021-12-17 | 南京大学 | 一种激活型近红外小分子荧光探针及其制备方法与应用 |
CN114377152A (zh) * | 2021-12-06 | 2022-04-22 | 中山大学 | 一种生物标志物响应型荧光示踪剂及其制备方法和应用 |
CN115947946A (zh) * | 2022-12-13 | 2023-04-11 | 中山大学 | 一种肾清除型双通道光学纳米探针及其制备方法和应用 |
CN115947777A (zh) * | 2022-12-30 | 2023-04-11 | 中山大学 | 一种近红外二区荧光化合物及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
FANG ZHIJUN等: "A 4-OTBS benzyl-based protective group for carboxylic acids", TETRAHEDRON LETTERS, vol. 60, 21 May 2019 (2019-05-21), pages 1658 - 1662, XP085707520, DOI: 10.1016/j.tetlet.2019.05.039 * |
HUANG JIAGUO等: "Zwitterionic near infrared fluorescent agents for noninvasive real-time transcutaneous assessment of kidney function", CHEM. SCI., vol. 8, 11 January 2017 (2017-01-11), pages 2652 - 2660 * |
LI YUYAO等: "A self-immobilizing near-infrared fluorogenic probe for sensitive imaging of extracellular enzyme activity in vivo", THE ROYAL SOCIETY OF CHEMISTRY, vol. 11, 13 May 2020 (2020-05-13), pages 5889 - 5894, XP093118452, DOI: 10.1039/D0SC01273D * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105073761B (zh) | 用于体外和体内成像和检测的取代的硅杂蒽阳离子红至近红外荧光染料 | |
CN114377152B (zh) | 一种生物标志物响应型荧光示踪剂及其制备方法和应用 | |
CN109336909A (zh) | 具有聚集诱导发光性质的近红外二区荧光化合物及制备方法、纳米粒胶束及其应用 | |
EP3969063B1 (en) | Modified cyanine dyes and conjugates thereof | |
Zhou et al. | Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye-conjugate with improved fluorescent yield | |
CN112266351B (zh) | 一种双光子比率荧光探针及其制备方法与应用 | |
EP1281405B1 (de) | Kurzkettige Peptid-Farbstoffkonjugate als Kontrastmittel für die optische Diagnostik | |
CN113979912B (zh) | 两种前列腺特异性膜抗原靶向荧光探针及其制备方法与应用 | |
US10004815B2 (en) | Near-infrared quenching group | |
KR20230026991A (ko) | 근적외선 시아닌 염료 및 그것의 콘쥬게이트 | |
CN109970780B (zh) | 近红外荧光化合物及制备方法、近红外荧光成像探针及其应用 | |
CN112574239B (zh) | 3-噻唑烯基氟化硼络合二吡咯甲川类化合物及其制备方法和用途 | |
CN115947946B (zh) | 一种肾清除型双通道光学纳米探针及其制备方法和应用 | |
CN116621820A (zh) | 一种两性离子荧光化合物及其制备方法和应用 | |
CN114410293B (zh) | 一种高灵敏度硫化氢响应型纳米探针及其制备方法和应用 | |
KR101924139B1 (ko) | 스쿠알레인 유도체 및 이를 포함하는 종양 진단용 근적외선 또는 광음향 이미징용 조성물 | |
CN115947777A (zh) | 一种近红外二区荧光化合物及其制备方法与应用 | |
CN114835710B (zh) | 双功能大环螯合物、偶联物、金属络合物及其应用 | |
CN117186151B (zh) | 一种近红外两性离子花菁染料及其制备方法和应用 | |
CN112521373B (zh) | 一种多模态探针及其制备方法和应用 | |
WO2016133913A1 (en) | Fluorescently labeled molecules containing modified tryptophan | |
Liu et al. | Molecular engineering of a commercially available NIR-II fluorescent cyanine dye for improved tumor targeting and imaging | |
Zhang et al. | Dynamic monitoring of the fibrosis disease by a collagen targeting near infrared probe | |
CN114380856B (zh) | 用于脑部硫化氢检测的硅罗丹明衍生物及制备方法与应用 | |
CN113004254B (zh) | 以吲哚氰绿衍生物为载体的配体及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |